Amir Tavakkol
Directeur Technique/Scientifique/R&D chez Timber Pharmaceuticals LLC
Profil
Amir Tavakkol currently works at Timber Pharmaceuticals LLC, as Chief Scientific Officer from 2019.
Dr. Tavakkol also formerly worked at Merck & Co., Inc., as Executive Director-Project Leadership, Schering-Plough Corp., as Senior Director, Novartis Pharmaceuticals Corp., as Clinical Director-Lamisil & Famvir, Colgate-Palmolive Co., as Principal, Viamet Pharmaceuticals, Inc., as Chief Development Officer from 2014 to 2017, the University of Michigan, as Professor-Dermatology Department, Topica Pharmaceuticals, Inc., as Senior VP-Clinical Development & Operations from 2011 to 2014, Castle Creek Biosciences, Inc., as Chief Development Officer from 2017 to 2018, and Timber Pharmaceuticals, Inc., as Chief Scientific Officer from 2020 to 2021.
Dr. Tavakkol received his doctorate degree in 1984 from The University of Manchester.
Postes actifs de Amir Tavakkol
| Sociétés | Poste | Début |
|---|---|---|
Timber Pharmaceuticals LLC
 Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Anciens postes connus de Amir Tavakkol
| Sociétés | Poste | Fin |
|---|---|---|
| TREX WIND-DOWN, INC. | Directeur Technique/Scientifique/R&D | 04/02/2021 |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/09/2018 |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/10/2017 |
Topica Pharmaceuticals, Inc.
 Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Directeur des opérations | 01/07/2014 |
| COLGATE-PALMOLIVE COMPANY | Corporate Officer/Principal | - |
Formation de Amir Tavakkol
| The University of Manchester | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| COLGATE-PALMOLIVE COMPANY | Consumer Non-Durables |
| TREX WIND-DOWN, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Topica Pharmaceuticals, Inc.
Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
Timber Pharmaceuticals LLC
Timber Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Timber Pharmaceuticals LLC engages in the provision of biopharmaceutical services. It offers congenital ichthyosis, tuberous sclerosis complex, and localized scleroderma. The company was founded in 2019 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | Health Technology |
